| Filed On | Filing |
|---|---|
| 23 Oct 2026 |
8-K: Other Events
Disclaimer Aardvark Therapeutics, Inc. (“we”, “us,” “our” or the “Company”) does not (nor its respective affiliates, directors, members, officers, employees or agents) make any representation or warranty, express or implied, as to, and n... |
| 22 Oct 2026 |
8-K: Other Events
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data |
| 08 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Other Events
Brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/Roche |
| 17 Aug 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 11 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 12 Jun 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 14 May 2026 | 8-K: Other Events |
| 07 May 2026 | 8-K: Results of Operations and Financial Condition |
| 24 Mar 2026 | 8-K: Entry into a Material Definitive Agreement |
| 23 Mar 2026 | 8-K: Results of Operations and Financial Condition |
| 27 Feb 2026 | 8-K: Other Events |
| 12 Feb 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Other Events |
| 10 Feb 2026 | 8-K: Other Events |
| 12 Jan 2026 | 8-K: Other Events |
| 10 Dec 2025 | 8-K: Other Events |
| 13 Nov 2025 | 8-K: Results of Operations and Financial Condition |
| 06 Nov 2025 | 8-K: Other Events |
| 04 Nov 2025 | 8-K: Regulation FD Disclosure; Other Events |
| 09 Oct 2025 | 8-K: Other Events |
| 03 Sep 2025 | 8-K: Other Events |
Loading...
